Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
Ira M. Jacobson(Cornell University), Barbara Haber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peggy Hwang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cheng‐Yuan Peng(China Medical University), Eric Lawitz(The University of Texas at San Antonio Health Science Center), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christophe Hézode(Inserm), Eliav Barr(University of New Mexico), Anita Y. M. Howe(St. Paul's Hospital), Janice Wahl, Paul Y. Kwo(Palo Alto University)
Cited by 89
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k